Healthcare Services

An Important Factor Driving the Arteriovenous Malformations Market Is the Rising Demand For Minimally Invasive Procedures Fueling The Growth Of The Market Due To Faster Recovery And Reduced Complications

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Arteriovenous Malformations Market Over The Period 2026–2030?

The arteriovenous malformations market has witnessed significant expansion in recent times. Its value is forecast to climb from $3.1 billion in 2025 to $3.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical upward trend is attributable to breakthroughs in neuroimaging technologies, heightened clinical recognition of AVM conditions, the establishment of more specialized neurosurgical centers, the adoption of endovascular embolization methods, and the growth of neurological services in hospitals.

The arteriovenous malformations market size is anticipated to experience robust expansion over the coming years. It is projected to achieve a value of $4.37 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.1%. This projected growth throughout the forecast period primarily stems from an escalating demand for accurate diagnostics, increased investments in neurovascular research, a broader embrace of minimally invasive treatments, an intensified focus on customized treatment strategies, and the greater availability of sophisticated interventional devices. Significant patterns expected during this period encompass the growing integration of advanced neuroimaging diagnostics, an increase in the application of minimally invasive endovascular procedures, a heightened emphasis on prompt and precise diagnosis, the broadening of interdisciplinary treatment methodologies, and improved oversight of patient outcomes following treatment.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

What Drivers Are Expected To Influence The Arteriovenous Malformations Market During The Forecast Period?

The growing demand for minimally invasive procedures is anticipated to propel the arteriovenous malformations market forward. Minimally invasive procedures encompass surgical or therapeutic interventions performed through small incisions or catheter-based methods, aiming to reduce trauma, shorten recovery periods, and lower complications. The increasing preference for these surgeries stems from their quicker recovery times, as smaller incisions cause less tissue damage and accelerate healing. This enables patients to return to their daily routines more rapidly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are well-suited for minimally invasive procedures by allowing advanced techniques such as endovascular embolization, which employs catheters and image-guided interventions to alleviate abnormal blood flow without the necessity of open surgery, leading to reduced risks, shorter recovery times, and improved patient outcomes. For instance, in September 2023, data from the American Society of Plastic Surgeons showed that a total of 25,442,640 cosmetic minimally invasive procedures were performed in the US in 2023, indicating an increase from 23,672,269 procedures in 2022. This reflects a 7% growth in minimally invasive treatments for both genders in 2023. Consequently, the rising demand for minimally invasive procedures is driving the expansion of the arteriovenous malformations market. The increasing investment in biotechnology is projected to stimulate the growth of the arteriovenous malformations market going forward. Biotechnology involves the utilization of biological processes, organisms, or systems to develop products and technologies for healthcare. Enhanced investments in biotechnology are a result of breakthroughs in gene editing technologies like CRISPR, which facilitate precise genetic modifications alongside innovations in medicine. Arteriovenous malformations (AVMs) benefit from biotechnology through advancements in medical imaging, gene therapy, and minimally invasive treatments, leading to biotechnology-derived solutions such as targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. For instance, in August 2024, according to The BioIndustry Association (BIA), the UK’s life sciences and biotechnology sector recorded its most substantial investment quarter since the pandemic in 2024, securing $2.55 billion in the first two quarters of the year and surpassing the $2.32 billion raised in 2023. Therefore, the increasing investment in biotechnology is propelling the growth of the arteriovenous malformations market.

How Is The Arteriovenous Malformations Market Divided Into Its Major Segments?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

What Major Market Trends Are Driving Changes In The Arteriovenous Malformations Market?

Major companies within the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterile kit containing key components for administering liquid embolic agents to manage vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set features two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system within a single sterilized package, thus optimizing procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Who Are The Prominent Organizations Shaping The Arteriovenous Malformations Market?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Read the full arteriovenous malformations market report here:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is Forecast To Lead The Arteriovenous Malformations Market In Terms Of Market Size?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arteriovenous Malformations Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21888&type=smp

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Imaging Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Global Market Report

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Vascular Stent Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795